

## **Supplementary Material**

**Table 1.** Documents published as current clinical practice guideline on the website of the European Society of Cardiology

<b>Document (Year of publication)</b>	<b>Document type</b>	<b>In-/excluded</b>
Syncope (2018) <sup>1</sup>	Guideline	Included
ESC/ESH Arterial Hypertension (2018) <sup>2</sup>	Guideline	Included
Cardiovascular Diseases during Pregnancy (2018) <sup>3</sup>	Guideline	Included
ESC/EACTS Guidelines on Myocardial Revascularization (2018) <sup>4</sup>	Guideline	Included
Fourth Universal Definition of Myocardial Infarction(2018) <sup>5</sup>	Disease definition	Excluded
Acute Myocardial Infarction in patients presenting with ST-segment elevation (2017) <sup>6</sup>	Guideline	Included
Dual Antiplatelet Therapy (DAPT) (Focussed Update) (2017) <sup>7</sup>	Guideline	Included
Peripheral Arterial Diseases (2017) <sup>8</sup>	Guideline	Included
Valvular Heart Disease (2017) <sup>9</sup>	Guideline	Included
Dyslipidaemias (2016) <sup>10</sup>	Guideline	Included
CVD Prevention in Clinical Practice (2016) <sup>11</sup>	Guideline	Included
Acute and Chronic Heart Failure (2016) <sup>12</sup>	Guideline	Included
Atrial Fibrillation (2016) <sup>13</sup>	Guideline	Included
Position paper on cancer treatments & cardiovascular toxicity (2016) <sup>14</sup>	Position paper	Excluded
Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation (2015) <sup>15</sup>	Guideline	Included
Infective Endocarditis (2015) <sup>16</sup>	Guideline	Included
Pericardial Diseases (2015) <sup>17</sup>	Guideline	Included
Pulmonary Hypertension (2015) <sup>18</sup>	Guideline	Included
Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (2015) <sup>19</sup>	Guideline	Included
ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management (2014) <sup>20</sup>	Guideline	Included
Aortic Diseases (2014) <sup>21</sup>	Guideline	Included
Acute Pulmonary Embolism (2014) <sup>22</sup>	Guideline	Included
Hypertrophic Cardiomyopathy (2014) <sup>23</sup>	Guideline	Included
Diabetes, Pre-Diabetes and Cardiovascular Diseases developed with the EASD (2013) <sup>24</sup>	Guideline	Included
Stable Coronary Artery Disease (2013) <sup>25</sup>	Guideline	Included
Cardiac Pacing and Cardiac Resynchronization Therapy (2013) <sup>26</sup>	Guideline	Included
Grown-Up Congenital Heart Disease (2010) <sup>27</sup>	Guideline	Included
Device Therapy in Heart Failure (Focused Update) (2010) <sup>28</sup>	Guideline	Included
The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease (2007) <sup>29</sup>	Position paper	Excluded
Angiotensin Converting Enzyme Inhibitors in Cardiovascular Disease (Expert Consensus Document on) (2004) <sup>30</sup>	Position paper	Excluded
Antiplatelet Agents (Expert Consensus Document on the Use of) (2004) <sup>31</sup>	Position paper	Excluded
B-Adrenergic Receptor Blockers (Expert Consensus Document on) (2004) <sup>32</sup>	Position paper	Excluded

	Guideline	Included
ACC/AHA/ESC Supraventricular Arrhythmias (2003) <sup>33</sup>	Guideline	Included
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project (2003) <sup>34</sup>	Other	Excluded
Medical Practice Guidelines: Separating science from economics (2003) <sup>35</sup>	Other	Excluded
Chest Pain (Management of) (2002) <sup>36</sup>	Guideline (without structured recommendations)	Excluded
Neonatal Electrocardiogram (Guidelines for the interpretation of the) (2001) <sup>37</sup>	Guideline (without structured recommendations)	Excluded

**Table 2.** Classes and Levels of Evidence by Guideline and Type of Recommendation (ESC Guidelines)

Guideline (Year of publication)	N	Class I			Class II			Class III		
		LoE A	LoE B	LoE C	LoE A	LoE B	LoE C	LoE A	LoE B	LoE C
<i>General cardiology</i>	875	146	103	203	27	138	194	18	19	27
Syncope (2018) <sup>1</sup>	114	4	20	20	29	37	1	2	1	1
Therapeutic	53	2	8	5	17	18	1	1	1	1
Consultation	1									
Device intervention	27	2	4	2	7	10		1	1	
Functional intervention	7				4	3				
Life-style intervention	1			1						
Minimal-invasive intervention	3		1			2				
Other/multiple intervention(s)	5		3	2						
Pharmaceutical intervention	9				6	2	1			
Diagnostic	57	2	12	11	12	19		1		
Ambulatory test	4				2	2				
History	4			2		2				
Invasive test	6	2			3	1				
Non-invasive test/imaging	26		6	7	2	10		1		
Other/multiple test(s)	1		1							
Physical examination	12		2	2	4	4				
Risk assesment	1				1					
Unspecified test	3		3							
Other	4			4						
Definition statement	1			1						
Differential diagnosis	3			3						
<i>ESC/ESH Arterial Hypertension (2018)<sup>2</sup></i>	135	41	16	29	1	20	15	7	2	4
Therapeutic	101	39	8	16	1	14	11	7	2	3
Device intervention	1									1
Life-style intervention	12	6	2	2		1				1
Other/multiple intervention(s)	10	5		4			1			
Pharmaceutical intervention	63	22	6	9	1	7	9	6	1	2
Unspecified intervention	15	6		1		6	1	1		
Diagnostic	30	2	8	9		6	4			1
Laboratory test	4		2			1				1
Non-invasive test/imaging	20	2	3	6		5	4			
Risk assesment	5		3	2						

Guideline (Year of publication)	N	Class I			Class II			Class III		
		LoE A	LoE B	LoE C	LoE A	LoE B	LoE C	LoE A	LoE B	LoE C
Unspecified test	1			1						
Other	4			4						
Definition statement	4			4						
Cardiovascular Diseases during Pregnancy (2018) <sup>3</sup>	148	2	8	71	2	53		1	11	
Therapeutic	121	2	8	51	2	2	47	1	10	
Consultation	12			3			3	1	5	
Device intervention	2			1			1			
Functional intervention	14		1	6	2		5			
Life-style intervention	1						1			
Minimal-invasive intervention	10		1	2			7			
Open surgical intervention	13			5			8			
Other/multiple intervention(s)	2			2						
Pharmaceutical intervention	61	2	5	28			21			5
Unspecified intervention	6		1	4			1			
Diagnostic	26			20			6			
Invasive test	1			1						
Laboratory test	4			3			1			
Non-invasive test/imaging	12			8			4			
Risk assesment	7			7						
Unspecified test	2			1			1			
Other	1									1
Policy statement	1									1
Dyslipidaemias (2016) <sup>10</sup>	96	16	4	26	10	13	21	4	1	1
Therapeutic	50	9	4	4	2	12	13	4	1	1
Life-style intervention	2			1			1			
Pharmaceutical intervention	38	8	2	2	1	10	11	3		1
Unspecified intervention	10	1	2	1	1	2	1	1	1	
Diagnostic	43	6		21	8		8			
History	2			2						
Laboratory test	38	6		16	8		8			
Risk assesment	1			1						
Unspecified test	2			2						
Other	3	1		1			1			
Differential diagnosis	2	1		1						
Research results	1				1					

Guideline (Year of publication)	N	Class I			Class II			Class III		
		LoE A	LoE B	LoE C	LoE A	LoE B	LoE C	LoE A	LoE B	LoE C
CVD Prevention in Clinical Practice (2016) <sup>11</sup>	178	41	34	19	15	34	26	3	4	2
Therapeutic	64	19	15	2	4	13	6	2	2	1
Consultation	3	3								
Functional intervention	2				1	1				
Pharmaceutical intervention	26	6	4		3	6	2	2	2	1
Unspecified intervention	10	1	5			3	1			
Life-style intervention	23	9	6	2		3	3			
Diagnostic	43	6	2	10	10	8	3	1	2	1
History	2				1	1				
Laboratory test	23	6		6	9					2
Non-invasive test/imaging	2					1		1		
Risk assesment	10		1	4	1	1	2			1
Unspecified test	6		1			5				
Other	71	16	17	7	1	13	17			
Policy statement	71	16	17	7	1	13	17			
ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management (2014) <sup>20</sup>	121	7	11	32	1	27	29	1	6	7
Therapeutic	71	5	7	17	1	20	14		5	2
Device intervention	3			2						1
Functional intervention	2			2						
Life-style intervention	1			1						
Minimal-invasive intervention	7		2	1		2	1			1
Open surgical intervention	10		1			5	4			
Other/multiple intervention(s)	6	1				4				1
Pharmaceutical intervention	35	3	3	9	1	8	7		3	1
Unspecified intervention	7	1	1	2		1	2			
Diagnostic	43	2	4	11		6	13	1	1	5
Invasive test	7	1	2	2		1				1
Laboratory test	7					3	2	1		1
Non-invasive test/imaging	20	1		6		2	8		1	2
Risk assesment	2		2							
Unspecified test	7			3			3			1
Other	7			4		1	2			
Policy statement	7			4		1	2			

Guideline (Year of publication)	N	Class I			Class II			Class III		
		LoE A	LoE B	LoE C	LoE A	LoE B	LoE C	LoE A	LoE B	LoE C
Diabetes, Pre-Diabetes and Cardiovascular Diseases developed with the EASD (2013) <sup>24</sup>	83	35	10	6	13	13	13	2	3	1
Therapeutic	65	33	6	3	11	7		2	2	3
Consultation	3		1	1		1				
Device intervention	1	1								
Life-style intervention	9	6	2							1
Minimal-invasive intervention	5	2	1			2				
Open surgical intervention	1	1								
Pharmaceutical intervention	38	19	2		8	5		2	2	
Unspecified intervention	8	4		2			2			
Diagnostic	17	2	4	3	1	6				1
Laboratory test	6	1	3	2						
Risk assesment	7		1			5				1
Unspecified test	4	1		1	1	1				
Other	1				1					
Policy statement	1				1					
<i>Coronary artery disease</i>	726	122	101	149	34	113	149	13	24	21
ESC/EACTS Guidelines on Myocardial Revascularization (2018) <sup>4</sup>	238	40	30	40	16	45	51	4	7	5
Therapeutic	213	38	26	37	15	37	45	4	7	4
Consultation	2			2						
Device intervention	1					1				
Functional intervention	1			1						
Minimal-invasive intervention	65	16	9	11	3	7	10	3	5	1
Open surgical intervention	62	8	10	11	1	13	17			2
Other/multiple intervention(s)	4	2	1	1						
Pharmaceutical intervention	77	12	6	10	11	17	17	1	2	1
Unspecified intervention	1			1						
Diagnostic	25	2	4	3	1	8	6			1
Invasive test	4	1				3				
Laboratory test	2			1		1				
Non-invasive test/imaging	13	1	2	1	1	3	4			1
Risk assesment	6		2	1		1	2			
Acute Myocardial Infarction in patients presenting with ST-segment elevation (2017) <sup>6</sup>	160	26	19	47	8	15	29	3	9	4

Guideline (Year of publication)	N	Class I			Class II			Class III		
		LoE A	LoE B	LoE C	LoE A	LoE B	LoE C	LoE A	LoE B	LoE C
Therapeutic	124	24	16	26	8	12	24	3	9	2
Functional intervention	5			3		1	1			
Life-style intervention	2	1		1						
Minimal-invasive intervention	32	10	6	4	1	1	6	2	2	
Open surgical intervention	1						1			
Other/multiple intervention(s)	5	1		1	1	1			1	
Pharmaceutical intervention	77	12	10	16	5	9	16	1	6	2
Unspecified intervention	2			1	1					
Diagnostic	29	1	3	16		3	4			2
Invasive test	6	1		4		1				
Laboratory test	4			4						
Non-invasive test/imaging	18		3	7		2	4			2
Other/multiple test(s)	1			1						
Other	7	1		5			1			
Policy statement	7	1		5			1			
Dual Antiplatelet Therapy (DAPT) (Focussed Update) (2017) <sup>7</sup>	64	10	5	7	4	17	16	1	3	1
Therapeutic	62	10	5	6	4	17	16		3	1
Minimal-invasive intervention	1	1								
Other/multiple intervention(s)	1				1					
Pharmaceutical intervention	60	9	5	6	3	17	16		3	1
Diagnostic	1						1			
Laboratory test	1						1			
Other	1			1						
Policy statement	1			1						
Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation (2015) <sup>15</sup>	134	30	23	26	6	16	25	1	4	3
Therapeutic	106	26	16	17	5	14	20	1	4	3
Device intervention	2	1					1			
Functional intervention	1			1						
Life-style intervention	1	1								
Minimal-invasive intervention	18	7	1	3	1	4	1			1
Open surgical intervention	4	1	1	1		1				
Other/multiple intervention(s)	1				1					
Pharmaceutical intervention	77	15	14	12	3	8	18	1	3	3

Guideline (Year of publication)	N	Class I			Class II			Class III		
		LoE A	LoE B	LoE C	LoE A	LoE B	LoE C	LoE A	LoE B	LoE C
Unspecified intervention	2	1					1			
Diagnostic	26	4	7	7	1	2	5			
Invasive test	5		3		1		1			
Laboratory test	6	1	2	2			1			
Non-invasive test/imaging	11	2	1	5			3			
Other/multiple test(s)	1	1								
Risk assessment	2		1				1			
Unspecified test	1						1			
Other	2			2						
Policy statement	2			2						
Stable Coronary Artery Disease (2013) <sup>25</sup>	130	16	24	29	20	28	4	1	1	8
Therapeutic	58	15	12	6	13	6	3	1	1	2
Consultation	2			2						
Functional intervention	4				2	1	1			
Minimal-invasive intervention	21	7	5	1	5		1	1	1	1
Pharmaceutical intervention	29	7	7	2	6	5	1			1
Unspecified intervention	2	1		1						
Diagnostic	70	1	12	21	7	22	1			6
Ambulatory test	3			1		2				
Invasive test	8			3		4				1
Laboratory test	12	1	3	5		2		1		
Non-invasive test/imaging	44		7	11	7	14				5
Risk assessment	2		2							
Unspecified test	1			1						
Other	2			2						
Policy statement	2			2						
Vascular medicine	318	21	30	99	4	63	81	6	4	10
Peripheral Arterial Diseases (2017) <sup>8</sup>	128	13	10	30	4	33	28	3	2	5
Therapeutic	96	13	5	16	4	29	21	3	2	3
Life-style intervention	4	1	1	2						
Minimal-invasive intervention	27		1	4	2	13	5	1		1
Open surgical intervention	33	4		3	2	8	12	1	1	2
Pharmaceutical intervention	27	7	2	4		8	4	1	1	
Unspecified intervention	5	1	1	3						
Diagnostic	29		5	12	4	6				2

Guideline (Year of publication)	N	Class I			Class II			Class III		
		LoE A	LoE B	LoE C	LoE A	LoE B	LoE C	LoE A	LoE B	LoE C
Invasive test	4			1			2			1
Laboratory test	1					1				
Non-invasive test/imaging	16		5	7		2	2			
Other/multiple test(s)	2			2						
Risk assesment	5			2		1	1			1
Unspecified test	1						1			
Other	3			2			1			
Differential diagnosis	1						1			
Policy statement	2			2						
Aortic Diseases (2014) <sup>21</sup>	119	4	5	57		13	36		4	
Therapeutic	61	2	4	25		5	23		2	
Life-style intervention	3		1				1			1
Minimal-invasive intervention	15	1		7		2	5			
Open surgical intervention	24		1	7		2	13			1
Other/multiple intervention(s)	2		1				1			
Pharmaceutical intervention	9			7		1	1			
Unspecified intervention	8	1	1	4			2			
Diagnostic	58	2	1	32		8	13		2	
Laboratory test	5			1		2	1			1
Non-invasive test/imaging	32	1		20		3	8			
Risk assesment	7	1	1	2		1	1			1
Unspecified test	14			9		2	3			
Acute Pulmonary Embolism (2014) <sup>22</sup>	71	4	15	12		17	17	3	2	1
Therapeutic	38	2	10	7		9	7	2	1	
Minimal-invasive intervention	5					1	3			1
Open surgical intervention	3			2			1			
Other/multiple intervention(s)	1					1				
Pharmaceutical intervention	27	2	10	4		7	2	1	1	
Unspecified intervention	2			1			1			
Diagnostic	33	2	5	5		8	10	1	1	1
Invasive test	1						1			
Laboratory test	5			2		1	1			1
Non-invasive test/imaging	17	2	2	1		6	5	1		
Risk assesment	4		2	1			1			
Unspecified test	6		1	1			3			1

Guideline (Year of publication)	N	Class I			Class II			Class III		
		LoE A	LoE B	LoE C	LoE A	LoE B	LoE C	LoE A	LoE B	LoE C
<i>Congenital and valvular heart disease</i>	677	14	104	200	3	44	258		7	47
Valvular Heart Disease (2017) <sup>9</sup>	111		11	33	2	8	53		2	2
Therapeutic	107		11	31	2	8	51		2	2
Minimal-invasive intervention	10		2	1			7			
Open surgical intervention	68		6	26	1	3	32			
Pharmaceutical intervention	24		2	3	1	5	10		2	1
Unspecified intervention	5		1	1			2			1
Diagnostic	4			2			2			
Invasive test	3			2			1			
Non-invasive test/imaging	1						1			
Infective Endocarditis (2015) <sup>16</sup>	128	1	50	21	13	30		1	12	
Therapeutic	100		40	15	6	26		1	12	
Device intervention	6		1	2			3			
Functional intervention	3						1			2
Minimal-invasive intervention	1		1							
Open surgical intervention	24		9	4	6	5				
Pharmaceutical intervention	66		29	9			17		1	10
Diagnostic	24	1	10	6	3	4				
Laboratory test	4	1		2			1			
Non-invasive test/imaging	20		10	4	3	3				
Other	4				4					
Policy statement	4				4					
Pericardial Diseases (2015) <sup>17</sup>	112	4	11	40	1	11	36	1	8	7
Therapeutic	79	4	8	19	1	9	30	1	1	7
Functional intervention	7			1			6			
Minimal-invasive intervention	7		1			4	2			
Open surgical intervention	17		2	7		3	5			
Other/multiple intervention(s)	6		2	3		1				
Pharmaceutical intervention	38	4	3	7	1	1	15	1	6	
Unspecified intervention	4			1			2			1
Diagnostic	33		3	21		2	6			1
Invasive test	2			2						
Laboratory test	10		1	4		1	3			1
Non-invasive test/imaging	14		1	12			1			
Other/multiple test(s)	2			1		1				

Guideline (Year of publication)	N	Class I			Class II			Class III		
		LoE A	LoE B	LoE C	LoE A	LoE B	LoE C	LoE A	LoE B	LoE C
Unspecified test	5		1	2			2			
Pulmonary Hypertension (2015) <sup>18</sup>	221	9	28	61		12	91		3	17
Therapeutic	152	9	25	23		11	71		3	10
Consultation	2			2						
Functional intervention	2			1			1			
Life-style intervention	1									1
Minimal-invasive intervention	1			1						
Open surgical intervention	13			5			7			1
Other/multiple intervention(s)	2			1			1			
Pharmaceutical intervention	124	9	24	11		10	61		3	6
Unspecified intervention	7		1	2			2			2
Diagnostic	48		2	27		1	11			7
Invasive test	25			13		1	6			5
Laboratory test	2		1	1						
Non-invasive test/imaging	12		1	7			3			1
Other/multiple test(s)	1			1						
Risk assessment	1									1
Unspecified test	7			5			2			
Other	21		1	11			9			
Differential diagnosis	2						2			
Policy statement	19		1	11			7			
Grown-Up Congenital Heart Disease (2010) <sup>27</sup>	105	4	45			48			8	
Therapeutic	105		4	45			48			8
Minimal-invasive intervention	15			8			7			
Open surgical intervention	68		1	29			34			4
Pharmaceutical intervention	4		1				2			1
Unspecified intervention	18		2	8			5			3
<i>Heart failure and myocardial disease</i>	325	25	38	73	6	49	106	9	7	12
Acute and Chronic Heart Failure (2016) <sup>12</sup>	185	23	15	41	6	36	39	9	6	10
Therapeutic	129	20	13	12	6	31	22	9	6	10
Consultation	2	2								
Device intervention	21	6	3			6	3	2		1
Functional intervention	5			1		1	1		1	1
Life-style intervention	1			1						
Minimal-invasive intervention	9	1	1	1	1	2	2		1	

Guideline (Year of publication)	N	Class I			Class II			Class III		
		LoE A	LoE B	LoE C	LoE A	LoE B	LoE C	LoE A	LoE B	LoE C
Open surgical intervention	3			1			2			
Other/multiple intervention(s)	3			1			1		1	
Pharmaceutical intervention	81	11	9	5	5	21	11	7	4	8
Unspecified intervention	4			2			2			
Diagnostic	52	2	2	27			4	17		
Ambulatory test	1						1			
History	1						1			
Invasive test	11			3			1	7		
Laboratory test	5	1		4						
Non-invasive test/imaging	28	1	1	17			1	8		
Risk assesment	1			1						
Unspecified test	5			3			2			
Other	4	1		2			1			
Policy statement	4	1		2			1			
Hypertrophic Cardiomyopathy (2014) <sup>23</sup>	132	22	32		11	64		1	2	
Therapeutic	66		9	14		6	35		1	1
Consultation	4		1	3						
Device intervention	11		2			3	5		1	
Functional intervention	2			1			1			
Life-style intervention	2			1			1			
Minimal-invasive intervention	5			1			1	3		
Open surgical intervention	8		1	2			5			
Pharmaceutical intervention	32		5	6		2	18			1
Unspecified intervention	2						2			
Diagnostic	63		13	16		5	28			1
Ambulatory test	3			2			1			
Invasive test	11		1	3			6			1
Laboratory test	9		3	1			5			
Non-invasive test/imaging	34		6	9		4	15			
Other/multiple test(s)	2		1				1			
Risk assesment	4		2	1			1			
Other	3			2			1			
Policy statement	3			2			1			
Device Therapy in Heart Failure (Focused Update) (2010) <sup>28</sup>	8	2	1		2	3				

Guideline (Year of publication)	N	Class I			Class II			Class III		
		LoE A	LoE B	LoE C	LoE A	LoE B	LoE C	LoE A	LoE B	LoE C
Therapeutic	8	2	1			2	3			
Device intervention	8	2	1			2	3			
<i>Electrophysiology</i>	<i>610</i>	<i>32</i>	<i>113</i>	<i>111</i>	<i>12</i>	<i>128</i>	<i>168</i>	<i>7</i>	<i>18</i>	<i>21</i>
Atrial Fibrillation (2016) <sup>13</sup>	151	14	23	10	5	49	38	3	5	4
Therapeutic	122		11	17	7	4	39	33	3	4
Consultation	3				1			2		
Functional intervention	6			3	2			1		
Life-style intervention	2		1					1		
Minimal-invasive intervention	18		1	1			9	6		
Open surgical intervention	10					1	3	6		
Pharmaceutical intervention	77	9	12	3	3	24	15	3	4	4
Unspecified intervention	6		1			3	2			
Diagnostic	26		2	6	3	1	9	4		1
History	1						1			
Laboratory test	5		1			1	2			1
Non-invasive test/imaging	14			5	1		4	4		
Physical examination	1			1						
Risk assessment	5		1		2		2			
Other	3		1				1	1		
Policy statement	3		1				1	1		
Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (2015) <sup>19</sup>	246	11	48	65	1	42	65	3	5	6
Therapeutic	182		8	30	44	1	37	53	3	4
Consultation	2				1			1		
Device intervention	65		5	12	11	1	15	20		1
Functional intervention	9			1	6		1	1		
Life-style intervention	5			1	4					
Minimal-invasive intervention	43		1	11	5		14	9	2	1
Open surgical intervention	4			1	1			2		
Other/multiple intervention(s)	2						1	1		
Pharmaceutical intervention	50		2	4	14		6	19	2	2
Unspecified intervention	2				2					
Diagnostic	50		2	15	16		3	9	1	4
Ambulatory test	2		1	1						
History	1				1					

Guideline (Year of publication)	N	Class I			Class II			Class III		
		LoE A	LoE B	LoE C	LoE A	LoE B	LoE C	LoE A	LoE B	LoE C
Invasive test	13		2	3		1	3			4
Laboratory test	3			2			1			
Non-invasive test/imaging	24	1	9	6		2	5			1
Other/multiple test(s)	1			1						
Risk assessment	2		2							
Unspecified test	4		1	3						
Other	14	1	3	5		2	3			
Differential diagnosis	1					1				
Policy statement	12	1	3	5		1	2			
Research results	1						1			
Cardiac Pacing and Cardiac Resynchronization Therapy (2013) <sup>26</sup>	66	3	10	11	2	17	13	1	5	4
Therapeutic	65	3	10	11	1	17	13	1	5	4
Device intervention	65	3	10	11	1	17	13	1	5	4
Diagnostic	1				1					
Invasive test	1				1					
ACC/AHA/ESC Supraventricular Arrhythmias (2003) <sup>33</sup>	147	4	32	25	4	20	52	3	7	
Therapeutic	147	4	32	25	4	20	52	3	3	7
Device intervention	1	1								
Functional intervention	13		7	5		1				
Life-style intervention	3					3				
Minimal-invasive intervention	23		13	2		4	3			1
Open surgical intervention	1			1						
Other/multiple intervention(s)	4			4						
Pharmaceutical intervention	96	3	12	9	4	12	49	2	5	
Unspecified intervention	6			4				1	1	

## eReferences

- 1 Brignole M, Moya A, de Lange FJ, *et al.* 2018 ESC Guidelines for the diagnosis and management of syncope. *Eur Heart J* 2018; **39**: 1883–948.
- 2 Williams B, Mancia G, Spiering W, *et al.* 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J* 2018; **39**: 3021–104.
- 3 Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, *et al.* 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. *Eur Heart J* 2018; **39**: 3165–241.
- 4 Neumann F-J, Sousa-Uva M, Ahlsson A, *et al.* 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 2018; **40**: 87–165.
- 5 Thygesen K, Alpert JS, Jaffe AS, *et al.* Fourth universal definition of myocardial infarction (2018). *Eur Heart J* 2018; **40**: 237–69.
- 6 Ibanez B, James S, Agewall S, *et al.* 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J* 2017; **39**: 119–77.
- 7 Valgimigli M, Bueno H, Byrne RA, *et al.* 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. *Eur Heart J* 2017; **39**: 213–60.
- 8 Aboyans V, Ricco J-B, Bartelink M-LEL, *et al.* 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). *Eur Heart J* 2017; **39**: 763–816.
- 9 Baumgartner H, Falk V, Bax JJ, *et al.* 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2017; **38**: 2739–91.
- 10 Catapano AL, Graham I, De Backer G, *et al.* 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. *Eur Heart J* 2016; **37**: 2999–3058.
- 11 Piepoli MF, Hoes AW, Agewall S, *et al.* 2016 European Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J* 2016; **37**: 2315–81.
- 12 Ponikowski P, Voors AA, Anker SD, *et al.* 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2016; **37**: 2129–200.
- 13 Kirchhof P, Benussi S, Kotecha D, *et al.* 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016; **37**: 2893–962.
- 14 Zamorano JL, Lancellotti P, Rodriguez Muñoz D, *et al.* 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. *Eur Heart J* 2016; **37**: 2768–801.
- 15 Roffi M, Patrono C, Collet J-P, *et al.* 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 2015; **37**: 267–315.
- 16 Habib G, Lancellotti P, Antunes MJ, *et al.* 2015 ESC Guidelines for the management of infective endocarditis. *Eur Heart J* 2015; **36**: 3075–128.
- 17 Adler Y, Charron P, Imazio M, *et al.* 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. *Eur Heart J* 2015; **36**: 2921–64.
- 18 Galiè N, Humbert M, Vachery J-L, *et al.* 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J* 2015; **37**: 67–119.
- 19 Priori SG, Blomström-Lundqvist C, Mazzanti A, *et al.* 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. *Eur Heart J* 2015; **36**: 2793–867.
- 20 Kristensen SD, Knuuti J, Saraste A, *et al.* ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. *Eur Heart J* 2014; **35**: 2383–243.
- 21 Erbel R, Aboyans V, Boileau C, *et al.* 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. *Eur Heart J* 2014; **35**: 2873–926.
- 22 Konstantinides S V., Torbicki A, Agnelli G, *et al.* 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. *Eur Heart J* 2014; **35**: 3033–73.
- 23 Elliott PM, Anastasakis A, Borger MA, *et al.* 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. *Eur Heart J* 2014; **35**: 2733–79.
- 24 Ryden L, Standl E, Bartnik M, *et al.* ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Hear J Suppl* 2013; **34**: 3035–3087.
- 25 Montalescot G, Sechtem U, Achenbach S, *et al.* 2013 ESC guidelines on the management of stable coronary artery disease. *Eur Heart J* 2013; **34**: 2949–3003.
- 26 Brignole M, Auricchio A, Baron-Esquivias G, *et al.* 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. *Eur Heart J* 2013; **34**: 2281–329.
- 27 Baumgartner H, Bonhoeffer P, De Groot NMS, *et al.* ESC Guidelines for the management of grown-up congenital heart disease (new version 2010): The Task Force on the Management of Grown-up

- Congenital Heart Disease of the European Society of Cardiology (ESC). *Eur Heart J* 2010; **31**: 2915–57.
- 28 Dickstein K, Vardas PE, Auricchio A, *et al.* 2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. *Eur Heart J* 2010; **31**: 2677–87.
- 29 Cooper LT, Baughman KL, Feldman AM, *et al.* The role of endomyocardial biopsy in the management of cardiovascular disease: A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. *Eur Heart J* 2007; **28**: 3076–93.
- 30 Lopez-Send J, Swedberg K, McMurray J, *et al.* Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular diseaseThe Task Force on ACE-inhibitors of the European Society of Cardiology. *Eur Heart J* 2004; **25**: 1454–70.
- 31 Patrono C, Bachmann F, Baigent C, *et al.* Expert Consensus Document on the Use of Antiplatelet Agents The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. *Eur Heart J* 2004; **25**: 166–81.
- 32 Lopez-Send J, Swedberg K, McMurray J, *et al.* Expert consensus document on B-adrenergic receptor blockersThe Task Force on Beta-Blockers of the European Society of Cardiology. *Eur Heart J* 2004; **25**: 1341–62.
- 33 Blomström-Lundqvist C, Scheinman M, Aliot E, *et al.* Supraventricular Arrhythmias (ACC/AHA/ESC Guidelines for the Management of Patients with). 2003. <https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Supraventricular-Arrhythmias-ACC-AHA-ESC-Guidelines-for-the-Management-of-Patients> (accessed April 13, 2019).
- 34 Conroy RM, Pyoralab K, Fitzgerald AP, *et al.* Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J* 2003; **24**: 987–1003.
- 35 Priori SG, Klein W, Bassand J-P. Medical Practice Guidelines Separating science from economics. *Eur Heart J* 2003; **24**: 1962–4.
- 36 Erhardt L, Herlitz J, Bossaert L, *et al.* Task force on the management of chest pain. *Eur Heart J* 2002; **23**: 1153–76.
- 37 Schwartz PJ, Garson Jr A, Paul T, *et al.* Guidelines for the interpretation of the neonatal electrocardiogram. *Eur Heart J* 2002; **23**: 1329–44.